INTAS DRHP PDF
Read more about Intas Pharma files draft prospectus for IPO on Business Standard. Drug maker Intas Pharmaceuticals today said it has filed. Intas Pharmaceuticals, has filed its draft red herring prospectus (DRHP) with Securities and Exchange Board of India (SEBI) for an initial public. Intas Pharma DRHP News: Latest and Breaking News on Intas Pharma DRHP. Explore Intas Pharma DRHP profile at Times of India for photos, videos and latest .
|Published (Last):||5 December 2005|
|PDF File Size:||16.80 Mb|
|ePub File Size:||14.34 Mb|
|Price:||Free* [*Free Regsitration Required]|
Intas Pharma files for an IPO
New Delhi, May 26 RPG Life Sciences has sold its Gujarat-based biotechnology unit dghp Intas Pharmaceuticals for Rs 25 crore to focus on core areas of business and improve long-term competitiveness in a rapidly changing market. Hyderabad-based pharma giant Aurobindo snaps up Portuguese co for Rs crore. Email Enter a valid email address. According to sources, the company has begun the groundwork for the IPO and approached merchant itnas a couple of months ago.
Sun Pharma in early talks to buy Intas Pharma. Intas Pharma buys Spanish company’s hospital business.
Drug-maker Intas Pharmaceuticals has merged all its group companies and subsidiaries over concerns about low profits. All rights reserved Disclaimer. Monday, 31 December Visit Our Digital Magazine: Intas Pharma inats first etanercept biosimilar. MCI to probe foreign jaunts by MP doctors. It has also extended its presence into other therapy areas such intss gynecology, infertility, arthritis and the respiratory.
Mon, Dec 31, Updated Chandra kicks off divestment plan. The promoters of the company are Mr. Desi pharma companies top in biosimilars globally. It is currently ranked as the 12th largest pharmaceutical company in the country with a 2.
Intas Pharmaceuticals files DRHP for IPO
The company is present in various major therapy areas such as those relating to neurology, psychiatry, cardiology, pain management, gastroenterology, diabetology, nephrology, urology, anti-infective therapy, dermatology, gynecology, respiratory system, oncology, critical care and ophthalmology with a strong focus on chronic therapy areas relating to neurology, psychiatry, cardiology and diabetology.
From around the Web. Drugs sold sans regulator’s nod, safety studies. We will get in touch with you shortly. Intas Pharma is a vertically integrated Indian pharmaceutical company with global operations, engaged in the development, manufacture and marketing of pharmaceutical formulation. Rahul Gandhi listed as ‘non-Hindu’. Enquiry Thanks for contacting us! Web Interface Conceived and Powered By: Iintas said the group has started a process to sell drug discovery services company Advinus Therapeutics, drawing interest from private equity funds Kedaara Capital and True North as well as from strategic players, GVK Biosciences and Lambda, a unit of Intas Pharma.
Please fill the all fields. Please click here to Sign-in or Sign-up. In what could further strengthen its inas in European and non-European countries, Ahmedabad based Intas Pharmaceuticals Ltd has acquired hospital business of Combino Pharm in Spain and Portugal for an undisclosed sum. The Ahmedabad-based company is considering licensing agreements with hospital-based businesses in these markets.
Please note that comments are moderated and are generally published if they are on-topic and not abusive. Nimish Hasmukhbhai Chudgar, Dr. Intas Pharma inta for an IPO.
Medical Council of India MCI will investigate a complaint against 11 doctors from Madhya Pradesh who are charged with accepting foreign jaunts sponsored by pharmaceutical company. Binish Hasmukh Chudgar, Mr.
Its products are marketed in over 60 countries, either directly, through its subsidiaries or indirectly, through supply, distribution and other arrangements with various leading global pharmaceutical companies.
ChrysCap backs Curatio in latest pharma bet.
Intas Pharma merges group companies, subsidiaries. Intas Pharma eyes hospitals in Europe, US. Subscribe to BioSpectrum India. The IPO will be made through a public issue of equity shares of face value of Rs. At present, domestic companies are marketing their products only in emerging markets, but the largest and most lucrative market for all pharmaceuticals — the US — is the next stop.